Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA - Seite 4

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Contacts Sanofi:   Media Relations Jack Cox Tel: [phone] [e-mail]	Investor Relations Sébastien Martel Tel.: [phone] [e-mail]
Contacts Regeneron:   Media Relations Arleen Goldenberg Tel: [phone] Mobile: [phone] [e-mail]	Investor Relations Manisha Narasimhan, Ph.D. Tel: [phone] [e-mail]

---

^[1] Huizinga TWJ, Fleischmann RM, Jasson M, et al. "Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomized SARIL-RA-MOBILITY Part A trial." Annals of Rheumatic Diseases 2014; 73(9): 1626-1634.

^[2] Dayer JM, et al. Rheumatology (Oxford). 2010;49(1):15-24. 3. Rose-John S, et al. J Leukoc Biol. 2006;80(2):227-236.

^[3] Sanofi. Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 28 May 2015]. Available from: https://clinicaltrials.gov/show/NCT01061736 NLM Identifier: NCT01061736.

^[4] Sanofi. To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 28 May 2015]. Available from: NLM Identifier: https://clinicaltrials.gov/ct2/show/NCT01709578 NCT01709578.